Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2141-V11 in solid tumors with skin metastasis
NCT04059588Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Jan 2020
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 2141-V11 in solid tumor and melanoma, sponsored by The Rockefeller University. Primary endpoints: Treatment-emergent adverse events at 2 years, Dose-Limiting Toxicities at 2 years and 2 more. Started Jan 2020; status: completed.
02
Drugs
2141-V11
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT04059588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059588.